MDClone is a self-service healthcare data platform that generates synthetic data, statistically representative data not tied to real patients, so researchers, clinicians, and analysts can explore massive datasets without touching protected health information directly. The company was founded in Israel in 2016 and now serves major health systems, payers, and life sciences customers across the US, Canada, and Israel.
Instead of routing every data request through IT and a lengthy de-identification review, MDClone's ADAMS platform lets authorized users query and explore synthetic datasets that preserve the statistical patterns of real clinical data while removing re-identification risk, cutting research timelines from months to hours once deployed. The company has raised over $100 million to date, including a $63 million Series C, to expand this synthetic-data-first approach across health systems.
MDClone targets health system IT and analytics leadership, clinical researchers, and population-health teams working under strict patient-privacy constraints. Pricing isn't published and runs through enterprise sales, reflecting the platform's focus on hospital systems and large payers rather than individual practitioners.
